Copyright © Inderes 2011 - present. All rights reserved.

Nolato

60.50 SEK

-1.06 %

Less than 1K followers

NOLA B

NASDAQ Stockholm

Industrial Goods & Services

Industrials

-1.06 %
+1.51 %
-0.08 %
+2.02 %
+11.62 %
+12.24 %
+8.42 %
-21.38 %
+5,003.03 %

Nolato operates in the manufacturing industry and focuses on the development, manufacture and distribution of plastic components and systems for various industries. The company's products are used in sectors such as the automotive industry, medical technology and consumer electronics. The business is global with a main presence in Europe, North America and Asia. Nolato was founded in 1938 and is headquartered in Torekov, Sweden.

Read more
Market cap
16.3B SEK
Turnover
8.55M SEK
Revenue
9.66B
EBIT %
9.45 %
P/E
24.8
Dividend yield-%
2.48 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
5.2
2026

Annual report '25

6.5
2026

General meeting '26

6.5
2026

Interim report Q1'26

ShowingAll content types
Third party research

Nolato: No drama, just solid delivery - ABG

* More margin gains, 12% target now looking conservative* Adj. EBITA raised by 1-2% for '25e-'27e, mainly from Engineered* Trading at 14.5x '26e EV/EBITA vs. five-year average 15.3xMore margin gains, 12% target now looking conservativeNolato reported...

Nolato
Third party research

Nolato: Slight beat on adj. EBITA - ABG

* Adj. EBITA SEK 274m (+4% vs. ABG, +2% vs. IR consensus)* We expect consensus adj. EBITA to come up by 1-2%* 14.5x '26e EV/EBITA on pre-Q3 estimates (and on yesterday's close)Q3 outcomeSales came in at SEK 2,342m (+1% vs. ABG 2,324m, 0% vs. IR cons ...

Nolato

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Third party research

Nolato: Margin expansion starting to plateau - ABG

* Q3e: Medical stable, but negative seasonality* EBITA estimates cut by 2-3%, mainly for Engineered* Share trading at 14x '26e EV/EBITAQ3e: stable Medical, but a seasonal drop in marginsWe expect Nolato will report Q3 net sales of SEK 2,324m, down 3%...

Nolato
Third party research

Nolato: Margin train keeps going - ABG

Another impressive margin lift Nolato reported Q2 EBITA 5% and 7% above ABGSCe and IR consensus, respectively. The beat was broad-based, with better organic growth (2pp above ABGSCe), a better EBITA margin (0.4pp above ABGSCe, 0.6pp above cons), and ...

Nolato
Third party research

Nolato - Better across the board - ABG

Q2 outcome Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs. IR cons 2,351m), down 2% y-o-y, although organic growth was +4% (ABG +2%). EBITA came in at SEK 277m (+5% vs ABG 264m, +7% vs. cons 259m), for an EBITA margin of 11.6% (ABG 11.2%, cons 11.0...

Nolato
Third party research

Nolato: We expect a repeat of strong margins - ABG

Q2e: FX headwinds, but continued strong margins We expect Nolato to report Q2 net sales of SEK 2,345m, a y-o-y decline of 4%, of which +2% is organic and -6% from FX, driven mainly by the weaker USD. Following its CMD on 13 March, when Nolato raised ...

Nolato
Third party research

Nolato: Impressive margin lift - ABG

Impressive margin lift in both segments, EBITA +6% vs. cons We raise EBITA by 4-1%, of which -1pp from FX 16-14x '25e-'26e EV/EBITA, 60% of EBITA non-cyclical Medical Impressive margin lift in both segments Nolato reported Q1 sales 2% below Modular Finance...

Nolato
Third party research

Nolato: Bigger margin lift than expected - ABG

EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x '25e-'26e EV/EBITA on pre-Q1 estimates Q1 outcome Sales came in at SEK 2,453m (-3% vs. ABG SEK 2,527m, -2% vs. Modular Finance IR cons SEK 2,494m), up...

Nolato
Third party research

Nolato: Resilient Medical exposure in a chaotic market - ABG

Q1e: a solid quarter with EBITA up 11% y-o-y Higher estimates following ambitious new targets Medical (~60% of EBITA) should be resilient in a downturn Q1e: a solid quarter with EBITA up 11% y-o-y We expect Nolato to report Q1 net sales of SEK 2,527m...

Nolato
Third party research

Nolato: CMD recap: back to earnings growth focus - ABG

>12% EBITA margin target looks doable... ...more uncertainty on the 8% org. growth target, in our view Back to earnings growth focus after a couple years of putting out fires >12% EBITA margin target looks doable... On its Capital Markets Day today, ...

Nolato
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.